Mitsubishi Tanabe Pharma America Inc (MTPA), a subsidiary of Japan-based Mitsubishi Tanabe Pharma Corporation (MTPC), announced on Monday that it has changed its corporate name to Tanabe Pharma America Inc (TPA), effective immediately.

In July, MTPC said that it would change name to Tanabe Pharma Corporation, effective 1 December 2025, following its acquisition by private investment firm Bain Capital.

TPA will continue to pursue a robust pipeline of products for hard-to-treat diseases, including neurodegenerative diseases, inflammatory, and metabolic conditions, the company said.